WuXi PharmaTech (NYSE: WX) Holds the Groundbreaking Ceremony for its GLP Center in Suzhou
Oct 09, 2007
October 9, 2007 – Shanghai, China – WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced that its future GLP center in Suzhou started construction on September 29, 2007.
WuXi PharmaTech will build a 267,000 square foot state-of-the-art preclinical drug safety evaluation center situated in Wuzhong district, Suzhou, 60 kilometers from Shanghai. The center will provide customers with a broad range of highly value-added toxicology services. The company has already begun offering toxicology services at a smaller interim facility in Suzhou. The services to be provided at the new center will be more comprehensive and with much greater capacity. As an essential and integral part of drug R&D process, these new services will complement the current service offerings provided by the company. The center is expected to become the largest modern drug safety evaluation center in China after its completion in 2009.
Wuzhong district has been in the top ten rankings among one hundred most prosperous counties in China in terms of comprehensive economic strength for the last few years. It has excellent infrastructure, roads, communications and adequate power supply and other amenities, as well as its historical and culture heritage. With the government's strong support for the burgeoning pharmaceutical and biotechnology outsourcing industry, Wuzhong district is an ideal location for the accelerated future growth of WuXi PharmaTech.
"We are very excited to kick off the construction of this facility. The new facility, designed by a renowned and US architecture firm and to be managed by board certified toxicologist and other experienced scientists, will enable us to further broaden and expand our service capabilities and capacities to meet our customers' demands," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Wuzhong is an ideal location because of its proximity to Shanghai, animal resources and well-educated laboratory graduates. We greatly appreciate the support of the government of Suzhou," continued Dr. Li.
About WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.